Pfizer has announced a quarterly dividend of $0.43 per share for the first quarter of 2026, payable on March 6, 2026, marking its 349th consecutive quarterly dividend. The company is actively diversifying its growth engine post-COVID through new drug developments and strategic collaborations, including an exclusive global license agreement with YaoPharma for YP05002, an oral GLP-1 receptor agonist in Phase 1 for weight management. Additionally, Pfizer reports promising Phase 3 data for TUKYSA, a HER2-positive metastatic breast cancer therapy, which showed a 36% reduction in progression or death in first-line maintenance, potentially strengthening its oncology franchise. Despite progress, Pfizer faces ongoing challenges from pricing reforms, patent expirations, and execution risks, especially as it seeks to offset declining COVID revenue. Analysts project Pfizer's revenue to reach $59.6 billion and earnings of $12.8 billion by 2028, with a fair value estimate of $29.08, implying a 13% upside. Recent updates include optimistic forecasts from analysts and strategic moves to rebuild growth, but uncertainties remain around pricing and patent cliffs.